GHTC applauds yesterday's Senate passage of the Global Health Innovation Act, a bipartisan bill to support efforts by the US Agency for International Development to develop affordable, appropriate technologies to advance the health of people in the world’s poorest places. The bill, which has already passed the House of Representatives, now heads to the President’s desk where he is expected to sign it into law.
GHTC yesterday honored Senator Roy Blunt (R-MO) and Congresswoman Rosa DeLauro (D-CT) at its second annual Innovating for Impact Awards, which celebrates US policymakers and partnerships driving progress in global health innovation. GHTC also recognized the partnership that developed and introduced improved child-friendly tuberculosis (TB) medicines, making these transformative treatments available to children in need worldwide.
GHTC has opened nominations for its 2018 Innovating for Impact Awards. Now in its second year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is August 17, 2018.
GHTC welcomes the publication today by the World Health Organization (WHO) of its first Essential Diagnostics List, a critical new tool to help guide governments on the vital diagnostic tests that should be made available through health care systems.
The Trump Administration’s proposal to slash funding to fight global health threats like malaria, Ebola, and HIV/AIDS could cost states thousands of jobs and millions of dollars in economic investment and put the health of residents at risk, according to a new state-by-state analysis released today on Capitol Hill by the Global Health Technologies Coalition.
GHTC announced today changes to its membership structure to better serve its existing membership and engage a broader group of global health R&D stakeholders in its advocacy activities. Effective now, GHTC will begin offering three types of membership.
The United States has long led the world in developing vaccines, drugs, diagnostics, and other technologies for neglected diseases and conditions that affect the world’s most vulnerable people, and the President’s budget proposal threatens to undermine this scientific and humanitarian legacy.
GHTC welcomes yesterday’s passage by the US House of Representatives of the Global Health Innovation Act (H.R. 1660), a bipartisan bill that will strengthen efforts by the US Agency for International Development (USAID) to develop lifesaving drugs, vaccines, and other health technologies for people in need around the world.
Esteemed leaders from across the US government, industry, and the global health and medical research communities gathered at the Newseum in Washington, DC yesterday for GHTC’s Innovating for Impact Awards to celebrate US commitment to global health R&D and recognize Senator Chris Coons (D-DE) and Congressman Tom Cole (R-OK) for their congressional leadership on this issue. GHTC also honored the partnership that developed the dapivirine microbicide ring—a woman-centered HIV prevention tool—for its efforts to advance this groundbreaking new technology.
